<DOC>
	<DOCNO>NCT02093403</DOCNO>
	<brief_summary>This phase I trial study side effect best dose Selinexor give together decitabine treat patient acute myeloid leukemia return treatment ( relapse ) respond treatment ( refractory ) . Drugs use chemotherapy , decitabine Selinexor , work different way stop growth cancer cell , either kill cell stop dividing .</brief_summary>
	<brief_title>Decitabine Selinexor Treating Patients With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate safety tolerability Selinexor ( KPT‐330 ) combination decitabine patient acute myeloid leukemia ( AML ) . II . To define specific toxicity , maximum tolerate dose ( MTD ) dose limit toxicity ( DLT ) combination . III . To determine Recommended Phase 2 Dose ( RP2D ) combination . SECONDARY OBJECTIVES : I . To determine overall response rate ( ORR ) . II . To determine rate duration complete remission ( CR ) +/- hematological recovery KPT‐330 plus decitabine AML . III . To conduct pharmacodynamic study measure effect chemotherapy combination kinome , micronome epigenome . OUTLINE : This dose-escalation study selinexor . INDUCTION : Patients receive decitabine intravenously ( IV ) 1 hour day 1-10 Selinexor orally ( PO ) day 11 , 13 , 18 , 20 , 25 27 . Treatment repeat every 31 day 4 course absence disease progression unacceptable toxicity . MAINTENANCE : Patients receive decitabine IV 1 hour day 1-5 Selinexor PO day 6 , 8 , 13 , 15 , 20 22 . Courses repeat every 31 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients relapse refractory AML Newly diagnose elderly AML patient ( &gt; 60 year ) unfit intensive chemotherapy cytarabine anthracyclines also eligible trial give clinically beneficial therapy exist patient Patients secondary AML therapy related disease ( t‐AML ) eligible ; patient receive decitabine 5‐azacytidine prior treatment myelodysplastic syndrome ( MDS ) AML remain eligible ; however , none agent permit within 6 month study entry If patient co‐morbid medical illness , life expectancy attribute must great 6 month Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 Total bilirubin &lt; 2.0 mg/dL Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) &lt; 2.5 X institutional upper limit normal Creatinine &lt; 2.0 mg/d Glomerular filtration rate ( GFR ) &gt; 50 mL/min New York Heart Association ( NYHA ) congestive heart failure ( CHF ) class II good Female patient childbearing potential must agree use dual method contraception negative serum pregnancy test screening , male patient must use effective barrier method contraception sexually active female child ] bearing potential ; acceptable method contraception condom contraceptive foam , oral , implantable injectable contraceptive , contraceptive patch , intrauterine device , diaphragm spermicidal gel , sexual partner surgically sterilize postmenopausal ; male female patient , effective method contraception must use throughout study three month follow last dose Ability understand willingness sign write informed consent document Human immunodeficiency virus ( HIV ) infection without history acquire immune deficiency syndrome ( AIDS ) sufficiently high cluster differentiation ( CD ) 4 cell ( &gt; 400/mm^3 ) low HIV viral load ( &lt; 30,000 copies/ml plasma ) require anti‐HIV therapy eligible Patients must recover toxicity prior therapy less grade 2 Patients chemotherapy radiotherapy within 2 week ( 6 week nitrosoureas mitomycin C ) prior enter study Patients receive investigational agent patient receive investigational agent within 14 day enrollment Patients active central nervous system ( CNS ) malignancy ; asymptomatic small lesion consider active ; treat lesion may consider inactive stable least 3 month ; patient malignant cell cerebrospinal fluid ( CSF ) without CNS symptom may include Patients history allergic reaction attribute compound similar chemical biologic composition decitabine easily manage Major surgery within 2 week day 1 Uncontrolled active infection require parenteral antibiotic , antiviral , antifungal within one week prior first dose Known active hepatitis A , B , C infection ; know positive hepatitis C virus ( HCV ) ribonucleic acid ( RNA ) HBsAg ( hepatitis B virus [ HBV ] surface antigen ) Patients significantly diseased obstruct gastrointestinal tract uncontrolled vomit diarrhea History seizure , movement disorder cerebrovascular accident within past 3 year prior cycle 1 day 1 Patients macular degeneration , uncontrolled glaucoma , markedly decrease visual acuity Uncontrolled intercurrent illness include , limited , symptomatic congestive heart failure ( New York Heart Association [ NYHA ] class III IV ) , unstable angina pectoris , myocardial infarction within 6 month prior enrollment , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality ; prior study entry , electrocardiogram ( ECG ) abnormality screen document investigator medically relevant Patients serious medical psychiatric illness likely interfere participation clinical study Pregnant woman woman breastfeed exclude study ; confirmation subject pregnant must establish negative serum beta‐human chorionic gonadotropin ( beta‐hCG ) pregnancy test result obtain screening ; pregnancy test require post‐menopausal surgically sterilized woman Patients advanced malignant solid tumor exclude Patients renal failure ( GFR &lt; 50 mL/min ) exclude Patients opinion investigator significantly ideal body weight</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Adult Acute Myeloid Leukemia T ( 8 ; 21 ) ( Q22 ; Q22 )</keyword>
	<keyword>adult Acute Myeloid Leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult Acute Myeloid Leukemia del ( 5q )</keyword>
	<keyword>adult Acute Myeloid Leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
</DOC>